Results 31 to 40 of about 3,797 (192)
, 2015 Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy before liver transplantation (LT).
Adam Peyton +15 more
core +2 more sources
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial [PDF]
, 2014 Background & AimsSimeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir with peg-interferon α-2a and ribavirin (PR) in a randomized, double-blind, placebo-controlled ...
Ronald Kalmeijer +32 more
core +1 more source
Medicine Science, 2018 Chronic infection with HCV is a worldwide health problem that may lead to cirrhosis, portal hypertension, hepatocellular failure and hepatocellular carcinoma in most of cases.
Engy A. Wahsh +4 more
doaj +1 more source
The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]
African Journal of Gastroenterology and Hepatology, 2019 Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail +2 more
doaj +1 more source
Modular Synthesis of Pyritide‐Inspired Macrocycles Featuring Bipyridine Motifs
Angewandte Chemie, Volume 137, Issue 51, December 15, 2025.A pyritide‐inspired build/couple/pair strategy yields a diverse macrocycle library. This approach expands chemical space and enables the discovery of 6paW, a potent anti‐ferroptotic agent. Abstract Macrocycles represent a promising class of drug‐like scaffolds with unique structural features and the ability to engage challenging targets such as protein–
Ji Hyae Lee +4 more
wiley +2 more sources
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). [PDF]
PLoS ONE, 2016 Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of ...
Tarik Asselah +13 more
doaj +1 more source
Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder
Pregnancy, Volume 2, Issue 5, September 2026.Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin +19 more
wiley +1 more source
Eligibility for 12-week simeprevir plus PR regimen according to patient baseline characteristics.
, 2017 Eligibility for 12-week simeprevir plus PR regimen according to patient baseline characteristics.
Christophe Moreno (798309) +14 more
core +1 more source
European Journal of Case Reports in Internal Medicine, 2015 Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment.
Rafael Mahieu +5 more
doaj +1 more source
Bulletin of the National Research Centre, 2021 Background Hepatitis C virus (HCV) is a global medical condition that causes several life-threatening chronic diseases in the liver. The conventional interferon-free treatment regimens are currently in use by a blend of direct-acting antiviral agents ...
Stephen Ejeh +3 more
doaj +1 more source